More on UCBJY
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $117.07 |
|
|||
| Open | $117.07 | ||||
| 52 Wk High | $46.25 | ||||
| 52 Wk Low | $32.74 | ||||
| Day High | $117.07 | ||||
| Day Low | $117.07 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 760 | ||||
- BofA Securities Reiterates Buy Rating on UCB (UCB:BB) (UCBJY)
- Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 Award
- Epilepsia Open publishes results of post hoc data analysis of FINTEPLA® (fenfluramine) in patients with Lennox-Gastaut syndrome
- UBS Reiterates Buy Rating on UCB (UCB:BB) (UCBJY)
- UCB (UCB:BB) (UCBJY) PT Lowered to EUR260 at Barclays
- Jefferies Upgrades UCB SA (UCB:BB) (UCBJY) to Hold
- UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.
- UCB (UCB:BB) (UCBJY) PT Raised to EUR305 at Berenberg
- UCB (UCB:BB) (UCBJY) PT Lowered to EUR320 at UBS
- UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
Entities mentioned with UCBJY
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- Dividend | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- Show More...
